Uma Sinha
Chief Tech/Sci/R&D Officer bei EIDOS THERAPEUTICS, INC.
Vermögen: 49 200 $ am 31.03.2024
Profil
Derzeit bekleidet Uma Sinha die Position des Chief Scientific Officer von BridgeBio Pharma, Inc. und des Chief Scientific Officer für Eidos Therapeutics, Inc. (eine Tochtergesellschaft von BridgeBio Pharma, Inc.). Dr. Sinha war zuvor Chief Scientific Officer bei Global Blood Therapeutics, Inc. und Principal bei COR Therapeutics, Inc. sowie Senior Director-Cardiovascular bei Millennium Pharmaceuticals, Inc. und Principal bei Genencor International, Inc. und Vice President & Head-Biology bei Portola Pharmaceuticals, Inc. Sie promovierte an der University of Georgia und erwarb einen Bachelor-Abschluss am Presidency College.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
PROKIDNEY CORP. CLASS A
0,05% | 29.06.2023 | 30 000 ( 0,05% ) | 49 200 $ | 31.03.2024 |
Aktive Positionen von Uma Sinha
Unternehmen | Position | Beginn |
---|---|---|
EIDOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.06.2016 |
BRIDGEBIO PHARMA, INC. | Chief Tech/Sci/R&D Officer | 01.04.2016 |
PROKIDNEY CORP. | Director/Board Member | - |
Ehemalige bekannte Positionen von Uma Sinha
Unternehmen | Position | Ende |
---|---|---|
GLOBAL BLOOD THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.06.2015 |
PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.12.2012 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | 01.01.2002 |
SOCL CAPI | Director/Board Member | - |
Genencor International, Inc.
Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Corporate Officer/Principal | - |
Ausbildung von Uma Sinha
University of Georgia | Doctorate Degree |
Presidency College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
BRIDGEBIO PHARMA, INC. | Health Technology |
PROKIDNEY CORP. | Health Technology |
Private Unternehmen | 7 |
---|---|
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Genencor International, Inc.
Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Health Technology |
Portola Pharmaceuticals LLC
Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Eidos Therapeutics, Inc.
Eidos Therapeutics, Inc. BiotechnologyHealth Technology Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
Social Capital Suvretta Holdings Corp. III
Social Capital Suvretta Holdings Corp. III Financial ConglomeratesFinance Social Capital Suvretta Holdings Corp. III is a blank check company, which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Henderson, NV. | Finance |
Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |